Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound Shows Enhanced Anti-tumor Activity When Combined with Either Venetoclax or Bendamustine in Diffuse Large B Cell Lymphoma (DLBCL) Mouse Models
Sivan Elloul, Hua Chang, Boris Klebanov, Trinayan Kashyap, Maxwell Werman, Margaret Lee, Yosef Landesman, Sharon Schacham, Michael Kaufmann and Sharon Friedlander
Karyopharm Therapeutics, Newton MA 02459

**ABSTRACT**

Additive Growth Inhibitory Effect and Down Regulation of DRR Proteins in Selinexor-Bendamustine Combination Treated DoHH2-Derived Xenografts

Selinexor-Venetoclax Combination is Synergistic in Toledo Model of DLBCL-Derived Xenografts

Down Regulation of BCL2, BCL6 and Induction of Apoptosis in Selinexor-venetoclax Treated DLBCL Xenograft models

**RESULTS**

Selinexor Synergizes with Venetoclax and Bendamustine to Reduce DLBCL Cell Viability

**CONCLUSIONS**

Selinexor is an excellent candidate partner for combination therapies in DLBCL. It shows enhanced antitumor effect with both bendamustine and venetoclax, modulating 30S and BCL2 pathway activity, respectively. These data provide rational support for study of selinexor-venetoclax and selinexor-bendamustine combination in clinical trials.